Price (GBP)
144.00 -% (-)
50UC5.75% NTS 13/11/31
Track 6 more instruments
Open / Last close
- / 144.00
High / Low
- / -
Bid / Offer
- / -
Maturity Date
13.11.31
As at 26.09.20 22:00:09 - All data delayed at least 15 minutes
6 more instruments

AstraZeneca Plc instruments

Select instrument to view
Equity (2)
Code Instrument name Price Change Type Documentation
AZNORD SHS $0.258,576.00
GBX
0.20%Equity-
0A4JASTRAZENECA ADR REPRESENTING 1.5 ORD SHS-
USD
-Equity-
Bonds (5)
Code Instrument name Price Maturity Type Documentation
50UC5.75% NTS 13/11/31144.00
GBP
13.11.31Bonds-
35BR0.750% NTS 12/05/24-
EUR
12.05.24Bonds-
35BZ1.250% NTS 12/05/28-
EUR
12.05.28Bonds-
35CA0.250% NTS 12/05/21-
EUR
12.05.21Bonds-
43ER0.875% NTS 24/11/21-
EUR
24.11.21Bonds-

Instrument information

What's this?
Market
Main Market
Issue date
14 November 2007
Maturity date
13 November 2031
Amount issued (m)
-
Coupon rate
-
Coupon type
-
Coupon frequency
-
Expected next coupon payment date*
-
Yield to maturity
-
ISIN
XS0330497149
SEDOL
B292X01
Market identifier code (MIC)
XLON
Trading service
Fixed interest (Trade reporting Only)
Market segment
CWTR

Last 5 trades

What's this?
Date Time Price CurrencyVolume Trade ValueTrade type Trade flag MIC
Sorry, we couldn’t find any trades matching your search

Upcoming Events

from AstraZeneca Plc
AstraZeneca results and presentations
March 31st 2020, 11:00:00pm

Duration: + Add to my Calendar

Equity Research

from AstraZeneca Plc
An assessment of Astra’s COVID-19 vaccine journey

AstraZeneca (an inexperienced vaccine player) has emerged as top contender in the COVID-19 vaccine race, post its deal with Oxford University. The potential vaccine’s much-lower price and multiple out-licensing deals, resulting in major capacities being secured, have been two critical miles ...

View report
Growth continued in Q2, profitability better but more to be achieved

AstraZeneca reported a healthy Q2 growth, outperforming closer peers like Novartis and Roche. This healthy performance was largely driven by oncology (c.45% of group sales). Moreover, the group is a front-runner in the COVID-19 vaccine race. While there were some profitability improvements as wel ...

View report
AstraZeneca Gilead union is hard to digest

According to market rumours, AstraZeneca informally approached Gilead for a possible merger last month – if the deal goes ahead, it would be the biggest transaction in pharma industry to date. However, the strategic rationale for the deal appears limited – AstraZeneca and Gilead have ...

View report
Euphoric Q1 20 sales growth, despite high Chinese exposure

Despite being China-heavy, AstraZeneca had a superb start to 2020, with Q1 sales CER growth of 17%. While Oncology was once again the key growth driver, reasonable (but possibly transient) support came from ‘Respiratory + Immunology’, and New CVRM. However, a key question is – h ...

View report
SP Angel Healthcare Conditions

Novacyt (NCYT.L): Agreements struck with Bruker and Yourgene | Polarean Imaging (POLX.L): Change of General Meeting Venue | Silence Therapeutics (SLN.L): Strategic collaboration with AstraZeneca (AZN.L)

View report

Contacts

from AstraZeneca Plc
Thomas Kudsk Larsen
atAstraZeneca Plc
+44 203 749 5712
thomas.larsen@astrazeneca.com
Oncology
Henry Wheeler
atAstraZeneca Plc
+44 203 749 5797
henry.wheeler@astrazeneca.com
BioPharmaceuticals (CV, metabolism)
Christer Gruvris
atAstraZeneca Plc
+44 203 749 5711
christer.gruvris@astrazeneca.com
BioPharmaceuticals (respiratory, renal)
Nick Stone
atAstraZeneca Plc
+44 203 749 5716
nick.stone@astrazeneca.com
Other medicines
Josie Afolabi
atAstraZeneca Plc
+44 203 749 5631
josie.afolabi@astrazeneca.com
Finance, fixed income
Craig Marks
atAstraZeneca Plc
+44 7881 615 764
craig.marks@astrazeneca.com
Corporate access, retail investors
Jennifer Kretzmann
atAstraZeneca Plc
+44 203 749 5824
jennifer.kretzmann@astrazeneca.com
Issuer presentations live and on demand
Watch on Spark Live